Targeted therapies have allowed for better management of neuroendocrine tumors (NETs), yet this requires that healthcare providers glean new knowledge about treatment options such as somatostatin analogs. To improve provider competency and include consideration of patient perspectives in treatment selection, PlatformQ Health and Healing NET Foundation teamed up with the Moffitt Cancer Center to produce a free educational initiative for providers.
The one-hour CME activity was broadcast live in October 2021 and remains available on demand at OMedLive.com. Focused on real-world data and consensus guidelines related to somatostatin analogs (SSA) and peptide receptor radiotherapies (PRRT), the panel discussion was led by experts in the field from Moffitt Cancer Center and the Robert H. Lurie Comprehensive Cancer Center and featured patient perspectives, including interviews with real patients with SSA and PRRT experience.
The organizations presented the program outcomes at the 2022 NANETS Multidisciplinary NET Medical Symposium.
540 learners participated in the educational program, with 92% reporting that the activities positively impacted clinical practice and 96% of learners reporting that the activity positively impacted their patients’ experiences and outcomes, including increasing patient compliance. Notably, there were 92 write-in comments shared, including providers sharing that the program increased their understanding of the emerging therapies and helped them to better diagnose and manage NETs.